Allogene Therapeutics (ALLO) EBT (2018 - 2026)

Allogene Therapeutics has disclosed EBT across 9 years of filings, most recently posting -$42.8 million for Q1 2026.

• EBT for Q1 2026 came in at -$42.8 million, up 28.43% year-over-year; the trailing twelve-month figure through Mar 2026 was -$174.1 million (up 30.08% YoY), and the FY2025 annual result was -$190.9 million, up 25.77% from the prior year.
• EBT came in at -$42.8 million for Q1 2026 at Allogene Therapeutics, down from -$39.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$39.1 million in Q4 2025 to a low of -$97.0 million in Q1 2023.
• The 5-year median for EBT is -$65.2 million (2024), against an average of -$66.3 million.
• Across the five-year window, EBT plunged 5046.54% in 2022 and soared 36.6% in 2025, its largest moves.
• Allogene Therapeutics' EBT stood at -$93.6 million in 2022, then increased by 15.8% to -$78.8 million in 2023, then rose by 27.02% to -$57.5 million in 2024, then surged by 32.13% to -$39.1 million in 2025, then dropped by 9.63% to -$42.8 million in 2026.
• The last three EBT figures came in at -$42.8 million (Q1 2026), -$39.1 million (Q4 2025), and -$41.3 million (Q3 2025), per Business Quant data.